Biorestorative Therapies (BRTX)
(Delayed Data from NSDQ)
$1.36 USD
+0.05 (3.82%)
Updated May 14, 2024 04:00 PM ET
After-Market: $1.35 -0.01 (-0.74%) 7:58 PM ET
2-Buy of 5 2
F Value C Growth B Momentum D VGM
Brokerage Reports
Biorestorative Therapies, Inc. [BRTX]
Reports for Purchase
Showing records 21 - 40 ( 40 total )
Company: Biorestorative Therapies, Inc.
Industry: Medical - Biomedical and Genetics
Company: Biorestorative Therapies, Inc.
Industry: Medical - Biomedical and Genetics
Receives Japan PTO Allowance for ThermoStem Patent Application, Filed 10Q
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Biorestorative Therapies, Inc.
Industry: Medical - Biomedical and Genetics
Northwell Health to Participate in Phase 2 Trial Testing BRTX-100 in cLDD
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Biorestorative Therapies, Inc.
Industry: Medical - Biomedical and Genetics
Company: Biorestorative Therapies, Inc.
Industry: Medical - Biomedical and Genetics
Completes Patient Enrollment Required for Safety Run-In Component
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Biorestorative Therapies, Inc.
Industry: Medical - Biomedical and Genetics
Seeks FDA Approval to Develop BRTX-100 in Other Indications
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Biorestorative Therapies, Inc.
Industry: Medical - Biomedical and Genetics
Company: Biorestorative Therapies, Inc.
Industry: Medical - Biomedical and Genetics
Company: Biorestorative Therapies, Inc.
Industry: Medical - Biomedical and Genetics
USPTO Grants Allowance of 3rd ThermoStem Application in Metabolic Disease
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Biorestorative Therapies, Inc.
Industry: Medical - Biomedical and Genetics
Company: Biorestorative Therapies, Inc.
Industry: Medical - Biomedical and Genetics
Receives EU Notice of Allowance for BRTX-100 Manufacturing Process Patent
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Biorestorative Therapies, Inc.
Industry: Medical - Biomedical and Genetics
Company: Biorestorative Therapies, Inc.
Industry: Medical - Biomedical and Genetics
Company: Biorestorative Therapies, Inc.
Industry: Medical - Biomedical and Genetics
Meaningful Near-Term Inflection Point - Phase 2 cLDD Trial DSMB Meeting
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Biorestorative Therapies, Inc.
Industry: Medical - Biomedical and Genetics
Company: Biorestorative Therapies, Inc.
Industry: Medical - Biomedical and Genetics
Transfer of Coverage, Establishing Buy Rating and $15 Price Target
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J